Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction.
The aim of this study was to set up a method for quantification of plasma mitomycin C (MMC) concentrations during intravesical chemotherapy delivered in the presence of local bladder hyperthermia (HT). In comparison with existing methods, this assay, characterized by relative simplicity and efficiency, resulted in the facilitation of performance with nondedicated instrumentation or nonspecialized staff. Purification from plasma matrix was carried out by solid-phase extraction under vaccuum. The purified drug was then collected directly into the vials of the HPLC autosampler. Chromatographic analysis was performed on a reversed-phase C18 column with water:acetonitrile (85:15 by vol) as the mobile phase and the UV detector set at 365 nm. The use of porfiromycin as internal standard provided a method with good within-day precision (CV 6.0% at 5 micrograms/L, n = 6), linearity (0.5-50 micrograms/L), and specificity. The lower limit of detection (< or = 0.5 microgram/L) proved to be suitable for plasma pharmacokinetics monitoring in two tested patients treated with MMC + HT for superficial bladder cancer.
Paroni
R
R
Laboratory of Chromatography and Separative Techniques, I.R.C.C.S. H San Raffaele, Milano, Italy.
Arcelloni
C
C
De Vecchi
E
E
Fermo
I
I
Mauri
D
D
Colombo
R
R
D000903:Antibiotics, Antineoplastic / Q000097:blood* / Q000493:pharmacokinetics; D002295:Carcinoma, Transitional Cell / Q000097:blood* / Q000628:therapy; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D006979:Hyperthermia, Induced; D007700:Kinetics; D016685:Mitomycin / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011786:Quality Control; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin